Cardiovascular Systems (CSII) 10-Q 4 Nov 13 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Sep. 30, 2013	Oct. 28, 2013
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'CSII	'
Entity Registrant Name	'CARDIOVASCULAR SYSTEMS INC	'
Entity Central Index Key	'0001180145	'
Current Fiscal Year End Date	'--09-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	25,702,393

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$63,227	$67,897
Accounts receivable, net	15,271	14,730
Inventories	8,266	6,243
Prepaid expenses and other current assets	1,231	959
Total current assets	87,995	89,829
Property and equipment, net	3,022	2,999
Patents, net	3,418	3,219
Debt conversion option and other assets	685	850
Total assets	95,120	96,897
Current liabilities	'	'
Current maturities of long-term debt	5,074	5,095
Accounts payable	8,520	7,230
Deferred grant incentive	151	156
Accrued expenses	10,209	9,932
Total current liabilities	23,954	22,413
Long-term liabilities	'	'
Long-term debt, net of current maturities	5,742	7,472
Other liabilities	153	180
Total long-term liabilities	5,895	7,652
Total liabilities	29,849	30,065
Commitments and contingencies	'	'
Common stock, $0.001 par value; authorized 100,000,000 common shares at September 30, 2013 and June 30, 2013; issued and outstanding 25,220,534 at September 30, 2013 and 24,382,025 at June 30, 2013, respectively	25	24
Additional paid in capital	269,725	261,722
Common stock warrants	6,088	8,361
Accumulated deficit	-210,567	-203,275
Total stockholders’ equity	65,271	66,832
Total liabilities and stockholders’ equity	$95,120	$96,897

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Common stock, par value (in usd per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,220,534	24,382,025
Common stock, shares outstanding	25,220,534	24,382,025

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Revenues	$29,766	$23,293
Cost of goods sold	6,864	5,254
Gross profit	22,902	18,039
Expenses	'	'
Selling, general and administrative	25,371	20,023
Research and development	4,378	3,222
Total expenses	29,749	23,245
Loss from operations	-6,847	-5,206
Interest and other, net	-445	-4
Net loss and comprehensive loss	($7,292)	($5,210)
Net loss and comprehensive loss per common share:	'	'
Basic and Diluted (in usd per share)	($0.29)	($0.26)
Weighted average common shares used in computation:	'	'
Basic and Diluted (in shares)	24,751,368	20,397,004

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities	'	'
Net loss	($7,292)	($5,210)
Adjustments to reconcile net loss to net cash used in operations	'	'
Depreciation of property and equipment	293	204
Amortization and write-off of patents	28	34
Provision for doubtful accounts	90	80
Amortization of (premium) discount on debt, net	-8	-21
Debt conversion and valuation of conversion options, net	142	-388
Stock-based compensation	2,300	1,755
Changes in assets and liabilities	'	'
Accounts receivable	-631	97
Inventories	-2,023	99
Prepaid expenses and other assets	11	401
Accounts payable	1,329	-156
Accrued expenses and other liabilities	143	1,313
Net cash used in operations	-5,618	-1,792
Cash flows from investing activities	'	'
Expenditures for property and equipment	-287	-164
Costs incurred in connection with patents	-124	-160
Net cash used in investing activities	-411	-324
Cash flows from financing activities	'	'
Exercise of stock options and warrants	2,559	0
Payments on long-term debt	-1,200	-1,200
Net cash provided by (used in) financing activities	1,359	-1,200
Net change in cash and cash equivalents	-4,670	-3,316
Cash and cash equivalents	'	'
Beginning of period	67,897	35,529
End of period	$63,227	$32,213

Business_Overview

Business Overview	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business Overview	'
	Business Overview
	Company Description
	Cardiovascular Systems, Inc. was incorporated as Replidyne, Inc. in Delaware in 2000. On February 25, 2009, Replidyne, Inc. completed its reverse merger with Cardiovascular Systems, Inc., a Minnesota corporation incorporated in 1989 (“CSI-MN”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 3, 2008 (the “Merger Agreement”). Pursuant to the Merger Agreement, CSI-MN continued after the merger as the surviving corporation and a wholly-owned subsidiary of Replidyne. At the effective time of the merger, Replidyne, Inc. changed its name to Cardiovascular Systems, Inc. (“CSI”) and CSI-MN merged with and into CSI, with CSI continuing after the merger as the surviving corporation.
	The Company develops, manufactures and markets devices for the treatment of vascular diseases. The Company’s peripheral arterial disease products, the Stealth 360° PAD System, Diamondback 360° PAD System, and Predator 360° PAD System, are catheter-based platforms capable of treating a broad range of plaque types, including calcified plaque, in leg arteries both above and below the knee and address many of the limitations associated with existing treatment alternatives.
	In October 2013, the Company received premarket approval (“PMA”) from the FDA to market the Diamondback 360® Coronary Orbital Atherectomy System (“OAS”) as a treatment for severely calcified coronary arteries. The Company began a controlled commercial launch of the Diamondback 360® Coronary OAS following receipt of PMA approval.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Interim Financial Statements
	The Company has prepared the unaudited interim consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The year-end consolidated balance sheet was derived from the Company’s audited consolidated financial statements, but does not include all disclosures as required by GAAP. These interim consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to state fairly the Company’s consolidated financial position, the results of its operations and its cash flows for the interim periods. These interim consolidated financial statements should be read in conjunction with the consolidated annual financial statements and the notes thereto included in the Form 10-K filed by the Company with the SEC on September 11, 2013. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
	Fair Value of Financial Instruments
	The Company has adopted fair value guidance issued by the Financial Accounting Standards Board (“FASB”), which provides a framework for measuring fair value under GAAP and expands disclosures about fair value measurements.
	The fair value guidance classifies inputs into the following hierarchy:
	Level 1 Inputs — quoted prices in active markets for identical assets and liabilities
	Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities
	Level 3 Inputs — unobservable inputs
	The following table sets forth the fair value of the Company’s financial instruments that were measured on a recurring basis as of September 30, 2013. Assets are measured on a recurring basis if they are remeasured at least annually:
		Level 3
		Conversion
		Option
	Balance at June 30, 2013	$	716
	Conversion of convertible notes	(81		)
	Change in conversion option valuation	(61		)
	Balance at September 30, 2013	$	574
	The fair value of the debt conversion option is related to the loan and security agreement with Partners for Growth III, L.P. (described in Note 4) and has been included as a component of debt conversion option and other assets on the balance sheet. The Monte Carlo option pricing model used to determine the value of the debt conversion option included various inputs including expected volatility, stock price simulations, and assessed behavior of the Company and Partners for Growth based on those simulations. Based upon these inputs, the Company considers the conversion option to be a Level 3 investment. Significant increases (decreases) in any of these inputs in isolation would result in a significantly higher (lower) fair value measurement. The following assumptions were utilized in determining the fair value at September 30, 2013:
		September 30,
		2013
	Risk-free interest rate	0.3	%
	Contractual term	1.54 years
	Expected volatility	51.61	%
	As of September 30, 2013, the Company believes that the carrying amounts of its other financial instruments, including accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the short-term maturities of these instruments. The carrying amount of long-term debt approximates fair value based on interest rates currently available for debt with similar terms and maturities.
	Use of Estimates
	The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Stock-Based Compensation
	The Company recognizes stock-based compensation expense in an amount equal to the fair value of share-based payments computed at the date of grant. The fair value of all stock option and restricted stock awards are expensed in the consolidated statements of operations ratably over the related vesting period.
	Revenue Recognition
	The Company sells the majority of its products via direct shipment to hospitals or clinics. The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the sales price is fixed or determinable; and collectability is reasonably assured. The Company records estimated sales returns, discounts and rebates as a reduction of net sales in the same period revenue is recognized.
	Costs related to products delivered are recognized in the period revenue is recognized. Cost of goods sold consists primarily of raw materials, direct labor, and manufacturing overhead.

Selected_Consolidated_Financia

Selected Consolidated Financial Statement Information	3 Months Ended
	Sep. 30, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Consolidated Financial Statement Information	'
	Selected Consolidated Financial Statement Information
	Inventories
	Inventories are stated at the lower of cost or market with cost determined on a first-in, first-out (“FIFO”) method of valuation. The establishment of inventory allowances for excess and obsolete inventories is based on estimated exposure on specific inventory items.
	At September 30, 2013 and June 30, 2013, respectively, inventories were comprised of the following:
		September 30, 2013		June 30, 2013
	Inventories
	Raw materials	$	3,146	$	2,477
	Work in process	739		688
	Finished goods	4,381		3,078
		$	8,266	$	6,243

Debt

Debt	3 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	Loan and Security Agreement with Silicon Valley Bank
	On March 29, 2010, the Company entered into an amended and restated loan and security agreement with Silicon Valley Bank. The agreement was amended on December 27, 2011 to increase the size of the facility, and subsequently amended on June 29, 2012 to modify financial covenants and reduce the interest rate and other fees, and on May 10, 2013 to modify financial covenants. The agreement, as amended, includes a $12,000 term loan and a $15,000 line of credit. The terms of each of these loans are as follows:
	•	The $12,000 term loan has an initial interest rate of 8.0%, which can be reduced to 7.0% based on the achievement of positive EBITDA for the trailing six month period. The term loan has a maturity of 36 months, with repayment terms that include interest only payments during the first six months, followed by 30 equal principal payments of $400 plus interest, and a final payment of $100 due at maturity. This term loan also includes an acceleration provision that requires the Company to pay the entire outstanding balance, plus a penalty ranging from 1.0% to 3.0% of the commitment amount, upon prepayment or the occurrence and continuance of an event of default. The balance outstanding on the term loan at September 30, 2013 was $5,847 net of the unamortized discount associated with warrants issued to Silicon Valley Bank in connection with the loan. The unamortized discount associated with warrants and other fees paid to the lender are being amortized over the 36 month maturity period.
	•	The $15,000 line of credit expires on June 30, 2014 and has a floating interest rate equal to the Wall Street Journal’s prime rate, plus 1.25%, with an interest rate floor of 4.5%. Interest on borrowings is due monthly and the principal balance is due at maturity. Borrowings on the line of credit are based on 85% of eligible accounts. Accounts receivable receipts are deposited into a lockbox account in the name of Silicon Valley Bank. The line of credit is subject to non-use fees, annual fees, and cancellation fees. There was not an outstanding balance on the line of credit at September 30, 2013.
	Borrowings from Silicon Valley Bank are secured by all of the Company’s assets. The borrowings are subject to prepayment penalties and financial covenants, including maintaining certain liquidity and fixed charge coverage ratios. The Company was in compliance with all financial covenants as of September 30, 2013. Any non-compliance by the Company under the terms of debt arrangements could result in an event of default under the Silicon Valley Bank loan, which, if not cured, could result in the acceleration of this debt.
	Loan and Security Agreement with Partners for Growth
	On April 14, 2010, the Company entered into a loan and security agreement with Partners for Growth III, L.P. (PFG), as amended on August 23, 2011, December 27, 2011, June 30, 2012, and May 10, 2013. The amended agreement provides that PFG will make loans to the Company up to $5,000. The agreement has a maturity date of April 14, 2015. The loans bear interest at a floating per annum rate equal to 2.75% above Silicon Valley Bank’s prime rate, and such interest is payable monthly. The principal balance of and any accrued and unpaid interest on any notes are due on the maturity date and may not be prepaid by the Company at any time in whole or in part.
	As of September 30, 2013, PFG has provided the Company with the following four loans totaling $4,500 that are outstanding:
	Date of Loan	Amount			Conversion
		of Loan			Price
	7-Feb-13	$	1,000		$	15.26
	19-Feb-13	$	1,500		$	15.53
	27-Feb-13	$	1,500		$	15.8
	6-Mar-13	$	500		$	15.94
	At any time prior to the maturity date, PFG may at its option convert any of the outstanding loans into shares of the Company’s common stock at the applicable conversion price, which in each case equals the ten-day volume weighted average price per share of the Company’s common stock prior to the issuance date of each note. The Company may also effect at any time a mandatory conversion of amounts, subject to certain terms, conditions and limitations provided in the agreement, including a requirement that the ten-day volume weighted average price of the Company’s common stock prior to the date of conversion is at least 15% greater than the conversion price. The Company may reduce the conversion price to a price that represents a 15% discount to the ten-day volume weighted average price of its common stock to satisfy this condition and effect a mandatory conversion. The Company recorded an expense of $61 for the three months ended September 30, 2013 related to the change in fair value of the conversion options on all outstanding loans. This amount is a component of interest and other, net on the accompanying statement of operations. The balance outstanding under the loan and security agreement at September 30, 2013 was $4,719 including the net unamortized premium. The net unamortized premium associated with the loan, a beneficial conversion feature, and other fees paid to the lender is being amortized over the remaining maturity period.
	For the three months ended September 30, 2013, PFG loan conversion activity was as follows:
	Date of Conversion	Amount			Shares Issued
		Converted			Upon Conversion
	14-Aug-13	$	500		32,679
	The loans are secured by certain of the Company’s assets, and the agreement contains customary covenants limiting the Company’s ability to, among other things, incur debt or liens, make certain investments and loans, effect certain redemptions of and declare and pay certain dividends on its stock, permit or suffer certain change of control transactions, dispose of collateral, or change the nature of its business. In addition, the PFG loan and security agreement contains financial covenants requiring the Company to maintain certain liquidity and fixed charge coverage ratios. The Company was in compliance with all financial covenants at September 30, 2013. If the Company does not comply with the various covenants, PFG may, subject to various customary cure rights, decline to provide additional loans, require amortization of the loan over its remaining term, or require the immediate payment of all amounts outstanding under the loan and foreclose on any or all collateral, depending on which financial covenants are not maintained.
	As of September 30, 2013, debt maturities were as follows:
	Nine months ended June 30, 2014	$	3,850
	2015	6,900
	Total	$	10,750
	Less: Current Maturities	(5,074		)
	Long-Term Debt (excluding net unamortized premium)	$	5,676
	Add: Net Unamortized Premium	66
	Long-term debt	$	5,742
	Subsequent to September 30, 2013, PFG converted the $1,000 loan dated February 7, 2013 for 65,530 shares of the Company's common stock at a conversion price of $15.26 and the $1,500 loan dated February 19, 2013 for 96,586 shares of the Company’s common stock at a conversion price of $15.53.

Interest_and_Other_Net

Interest and Other, Net	3 Months Ended
	Sep. 30, 2013
Other Income and Expenses [Abstract]	'
Interest and Other, Net	'
	Interest and Other, Net
	Interest and other, net, includes the following:
		Three Months Ended
		September 30,
		2013			2012
	Interest expense, net of premium amortization	$	(281	)	$	(370	)
	Interest income	7			9
	Change in fair value of conversion option	(61		)	388
	Net write-offs upon conversion (option and unamortized premium)	(81		)	—
	Other	(29		)	(31		)
	Total	$	(445	)	$	(4	)

Stock_Options_and_Restricted_S

Stock Options and Restricted Stock Awards	3 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Options and Restricted Stock Awards	'
	Stock Options and Restricted Stock Awards
	The Company has a 2007 Equity Incentive Plan (the “2007 Plan”), which was assumed from CSI-MN, under which options to purchase common stock and restricted stock awards have been granted to employees, directors and consultants at exercise prices determined by the board of directors; and also in connection with the merger the Company assumed options and restricted stock awards granted by CSI-MN under its 1991 Stock Option Plan (the “1991 Plan”) and 2003 Stock Option Plan (the “2003 Plan”) (the 2007 Plan, the 1991 Plan and the 2003 Plan collectively, the “Plans”). The 1991 Plan and 2003 Plan permitted the granting of incentive stock options and nonqualified stock options. A total of 485,250 shares of common stock were originally reserved for issuance under the 1991 Plan, but with the approval of the 2003 Plan no additional options were granted under it. A total of 2,458,600 shares of common stock were originally reserved for issuance under the 2003 Plan, but with the approval of the 2007 Plan no additional options will be granted under it.
	The 2007 Plan originally allowed for the granting of up to 1,941,000 shares of common stock as approved by the board of directors in the form of nonqualified or incentive stock options, restricted stock awards, restricted stock unit awards, performance share awards, performance unit awards or stock appreciation rights to officers, directors, consultants and employees of the Company. The Plan was amended in February 2009 to increase the number of authorized shares to 2,509,969. Generally, options or shares granted under the 2007 Plan expire ten years from the date of grant and vest over three years. The amended 2007 Plan includes a renewal provision whereby the number of shares shall automatically be increased on the first day of each fiscal year ending on July 1, 2017, by the lesser of (i) 970,500 shares, (ii) 5% of the outstanding common shares on such date, or (iii) a lesser amount determined by the board of directors. On July 1, 2013, the number of shares available for grant was increased by 475,000 under the 2007 Plan renewal provision, which was 1.9% of shares outstanding at June 30, 2013.
	All options granted under the Plans become exercisable over periods established at the date of grant. The option exercise price is generally not less than the estimated fair market value of the Company’s common stock at the date of grant, as determined by the Company’s management and board of directors. In addition, the Company has granted nonqualified stock options to a director outside of the Plans.
	As of September 30, 2013, all outstanding options were fully vested. An employee's vested options must be exercised at or within 90 days of termination to avoid forfeiture.
	Stock option activity for the three months ended September 30, 2013 is as follows:
		Number of		Weighted
		Options(a)		Average
				Exercise Price
	Options outstanding at June 30, 2013	1,739,663		$	9.79
	Options exercised	(82,889	)	$	9.52
	Options outstanding at September 30, 2013	1,656,774		$	9.81
	(a)	Includes the effect of options granted, exercised, forfeited or expired from the 1991 Plan, 2003 Plan, 2007 Plan, and options granted outside the stock option plans described above.
	The fair value of each restricted stock award is equal to the fair market value of the Company’s common stock at the date of grant. Vesting of restricted stock awards generally ranges from one to three years. The estimated fair value of restricted stock awards, including the effect of estimated forfeitures, is recognized on a straight-line basis over the restricted stock’s vesting period.
	On September 4, 2013, the Company granted performance based restricted stock awards to certain executives. The performance based awards included grants of an aggregate of 53,566 shares that vest based upon achievement of certain thresholds measuring total shareholder return during periods within fiscal 2014 compared to a pre-determined peer group of companies, and grants of an aggregate of 53,566 shares that vest based upon achievement of certain thresholds measuring annual revenue growth during fiscal 2014 compared to a pre-determined peer group of companies.
	On July 24, 2013, the Company also granted performance based restricted stock awards comprising of 16,964 shares to certain executives for over-attainment of fiscal 2013 total shareholder return measures compared to a pre-determined peer group of companies. On September 11, 2013, the Company also granted performance based restricted stock awards comprising of 16,964 shares to certain executives for over-attainment of fiscal 2013 annual revenue growth measures compared to a pre-determined peer group of companies.  The related expense for the fiscal 2013 performance grants was recorded for the year ended June 30, 2013.
	Restricted stock award activity for the three months ended September 30, 2013 is as follows:
		Number of		Weighted
		Shares		Average  Fair
				Value
	Restricted stock awards outstanding at June 30, 2013	1,430,130		$	10.78
	Restricted stock awards granted	437,237		$	14.4
	Restricted stock awards forfeited	(37,103	)	$	10.96
	Restricted stock awards vested	(526,729	)	$	9.7
	Restricted stock awards outstanding at September 30, 2013	1,303,535		$	12.98

Common_Stock_Warrants

Common Stock Warrants	3 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Common Stock Warrants	'
	Common Stock Warrants
	Common stock warrant activity for the three months ended September 30, 2013 is as follows:
		Number of		Weighted
		Shares		Average
				Exercise  Price
	Common stock warrants outstanding at June 30, 2013	2,091,718		$	8.96
	Common stock warrants exercised	(424,237	)	$	9.15
	Common stock warrants outstanding at September 30, 2013	1,667,481		$	8.91
	Of the 424,237 warrants exercised during the three months ended September 30, 2013, 232,651 were cashless transactions resulting in an increase of $1,137 to additional paid-in capital with a corresponding decrease to common stock warrants.

Texas_Production_Facility

Texas Production Facility	3 Months Ended
	Sep. 30, 2013
Production Facility [Abstract]	'
Texas Production Facility	'
	Texas Production Facility
	Effective on September 9, 2009, the Company entered into an agreement with the Pearland Economic Development Corporation (the “PEDC”) for the construction and lease of an approximately 46,000 square foot production facility located in Pearland, Texas. The facility will primarily serve as an additional manufacturing location for the Company.
	The Company and the PEDC entered into a Corporate Job Creation Agreement dated June 17, 2009, which was subsequently amended July 2, 2012. The Job Creation Agreement, as amended, provided the Company with $2,975 in net cash incentive funds. The Company believes it will be able to comply with the conditions specified in the amended agreement. The PEDC will provide the Company with an additional $850 of net cash incentive funds in the following amounts and upon achievement of the following milestones:
	•	$425 upon the hiring of the 75th full-time employee at the facility on or before March 31, 2014, and maintaining 75 employees at the facility through March 31, 2015; and
	•	$425 upon the hiring of the 125th full-time employee at the facility on or before June 30, 2015, and maintaining 125 employees at the facility through June 30, 2016.
	In order to retain all of the cash incentives, the Company must maintain no fewer than 25 jobs at the Texas facility through June 30, 2015. Failure to meet this requirement will result in an obligation to make reimbursement payments to the PEDC as outlined in the amended agreement. The Company will not have any reimbursement requirements after June 30, 2015. As of September 30, 2013, the Company was in compliance with all minimum requirements under the amended agreement. The Company believes it will be able to comply with the conditions specified in the amended agreement.
	The Job Creation Agreement, as amended, also provided the Company with a net $1,020 award, of which $510 was received from the PEDC and the remainder is funded through the Texas Enterprise Fund program associated with the State of Texas. As of September 30, 2013, $340 has been received and the remaining $170 will be provided upon the hiring of the 75th full-time employee at the facility. The grant from the State of Texas is subject to reimbursement if the Company fails to meet certain job creation targets through 2014 and maintain these positions through 2020.
	The Company has presented the net cash incentive funds as a current and long-term liability on the balance sheet. The liabilities are reduced through the term of the agreement and recorded as an offset to expenditures incurred using a systematic methodology. As of September 30, 2013, the deferred grant incentive liabilities have been reduced by $3,562 in cumulative expenses, resulting in a remaining current liability of $151 and long-term liability of $51.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations:
		Three Months Ended
		September 30,
		2013			2012
	Numerator
	Net loss	$	(7,292	)	$	(5,210	)
	Denominator
	Weighted average common shares – basic	24,751,368			20,397,004
	Effect of dilutive stock options, warrants, convertible debt (a)(b)(c)	—			—
	Weighted average common shares outstanding – diluted	24,751,368			20,397,004
	Net loss per common share — basic and diluted	$	(0.29	)	$	(0.26	)
	(a)	At September 30, 2013 and 2012, 1,667,481 and 2,454,579 warrants, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
	(b)	At September 30, 2013 and 2012, 1,656,774 and 2,371,198 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
	(c)	At September 30, 2013 and 2012, 288,420 and 363,794 additional shares of common stock were issuable upon the conversion of outstanding convertible debt agreements. The effect of the shares that would be issued upon conversion of these debt agreements has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Interim Financial Statements	'
	Interim Financial Statements
	The Company has prepared the unaudited interim consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The year-end consolidated balance sheet was derived from the Company’s audited consolidated financial statements, but does not include all disclosures as required by GAAP. These interim consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to state fairly the Company’s consolidated financial position, the results of its operations and its cash flows for the interim periods. These interim consolidated financial statements should be read in conjunction with the consolidated annual financial statements and the notes thereto included in the Form 10-K filed by the Company with the SEC on September 11, 2013. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company has adopted fair value guidance issued by the Financial Accounting Standards Board (“FASB”), which provides a framework for measuring fair value under GAAP and expands disclosures about fair value measurements.
	The fair value guidance classifies inputs into the following hierarchy:
	Level 1 Inputs — quoted prices in active markets for identical assets and liabilities
	Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities
	Level 3 Inputs — unobservable inputs
Use of Estimates	'
	Use of Estimates
	The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company recognizes stock-based compensation expense in an amount equal to the fair value of share-based payments computed at the date of grant. The fair value of all stock option and restricted stock awards are expensed in the consolidated statements of operations ratably over the related vesting period.
Revenue Recognition	'
	Revenue Recognition
	The Company sells the majority of its products via direct shipment to hospitals or clinics. The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the sales price is fixed or determinable; and collectability is reasonably assured. The Company records estimated sales returns, discounts and rebates as a reduction of net sales in the same period revenue is recognized.
	Costs related to products delivered are recognized in the period revenue is recognized. Cost of goods sold consists primarily of raw materials, direct labor, and manufacturing overhead.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Assets Measured on a Recurring Basis	'
	The following table sets forth the fair value of the Company’s financial instruments that were measured on a recurring basis as of September 30, 2013. Assets are measured on a recurring basis if they are remeasured at least annually:
		Level 3
		Conversion
		Option
	Balance at June 30, 2013	$	716
	Conversion of convertible notes	(81		)
	Change in conversion option valuation	(61		)
	Balance at September 30, 2013	$	574
Fair Value Assumptions of Assets and Liabilities	'
	The following assumptions were utilized in determining the fair value at September 30, 2013:
		September 30,
		2013
	Risk-free interest rate	0.3	%
	Contractual term	1.54 years
	Expected volatility	51.61	%

Selected_Consolidated_Financia1

Selected Consolidated Financial Statement Information (Tables)	3 Months Ended
	Sep. 30, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Inventories	'
	At September 30, 2013 and June 30, 2013, respectively, inventories were comprised of the following:
		September 30, 2013		June 30, 2013
	Inventories
	Raw materials	$	3,146	$	2,477
	Work in process	739		688
	Finished goods	4,381		3,078
		$	8,266	$	6,243

Debt_Tables

Debt (Tables)	3 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Summary of Loans Outstanding	'
	As of September 30, 2013, PFG has provided the Company with the following four loans totaling $4,500 that are outstanding:
	Date of Loan	Amount			Conversion
		of Loan			Price
	7-Feb-13	$	1,000		$	15.26
	19-Feb-13	$	1,500		$	15.53
	27-Feb-13	$	1,500		$	15.8
	6-Mar-13	$	500		$	15.94
Summary of Loans Converted	'
	For the three months ended September 30, 2013, PFG loan conversion activity was as follows:
	Date of Conversion	Amount			Shares Issued
		Converted			Upon Conversion
	14-Aug-13	$	500		32,679
Debt Maturities	'
	As of September 30, 2013, debt maturities were as follows:
	Nine months ended June 30, 2014	$	3,850
	2015	6,900
	Total	$	10,750
	Less: Current Maturities	(5,074		)
	Long-Term Debt (excluding net unamortized premium)	$	5,676
	Add: Net Unamortized Premium	66
	Long-term debt	$	5,742

Interest_and_Other_Net_Tables

Interest and Other, Net (Tables)	3 Months Ended
	Sep. 30, 2013
Other Income and Expenses [Abstract]	'
Interest and Other, Net	'
	Interest and other, net, includes the following:
		Three Months Ended
		September 30,
		2013			2012
	Interest expense, net of premium amortization	$	(281	)	$	(370	)
	Interest income	7			9
	Change in fair value of conversion option	(61		)	388
	Net write-offs upon conversion (option and unamortized premium)	(81		)	—
	Other	(29		)	(31		)
	Total	$	(445	)	$	(4	)

Stock_Options_and_Restricted_S1

Stock Options and Restricted Stock Awards (Tables)	3 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Option Activity	'
	Stock option activity for the three months ended September 30, 2013 is as follows:
		Number of		Weighted
		Options(a)		Average
				Exercise Price
	Options outstanding at June 30, 2013	1,739,663		$	9.79
	Options exercised	(82,889	)	$	9.52
	Options outstanding at September 30, 2013	1,656,774		$	9.81
	(a)	Includes the effect of options granted, exercised, forfeited or expired from the 1991 Plan, 2003 Plan, 2007 Plan, and options granted outside the stock option plans described above.
Restricted Stock Award Activity	'
	Restricted stock award activity for the three months ended September 30, 2013 is as follows:
		Number of		Weighted
		Shares		Average  Fair
				Value
	Restricted stock awards outstanding at June 30, 2013	1,430,130		$	10.78
	Restricted stock awards granted	437,237		$	14.4
	Restricted stock awards forfeited	(37,103	)	$	10.96
	Restricted stock awards vested	(526,729	)	$	9.7
	Restricted stock awards outstanding at September 30, 2013	1,303,535		$	12.98

Common_Stock_Warrants_Tables

Common Stock Warrants (Tables)	3 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Common Stock Warrant Activity	'
	Common stock warrant activity for the three months ended September 30, 2013 is as follows:
		Number of		Weighted
		Shares		Average
				Exercise  Price
	Common stock warrants outstanding at June 30, 2013	2,091,718		$	8.96
	Common stock warrants exercised	(424,237	)	$	9.15
	Common stock warrants outstanding at September 30, 2013	1,667,481		$	8.91

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Reconciliation of Numerators and Denominators Used in Basic and Diluted Earnings Per Common Share Computations	'
	The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations:
		Three Months Ended
		September 30,
		2013			2012
	Numerator
	Net loss	$	(7,292	)	$	(5,210	)
	Denominator
	Weighted average common shares – basic	24,751,368			20,397,004
	Effect of dilutive stock options, warrants, convertible debt (a)(b)(c)	—			—
	Weighted average common shares outstanding – diluted	24,751,368			20,397,004
	Net loss per common share — basic and diluted	$	(0.29	)	$	(0.26	)
	(a)	At September 30, 2013 and 2012, 1,667,481 and 2,454,579 warrants, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
	(b)	At September 30, 2013 and 2012, 1,656,774 and 2,371,198 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
	(c)	At September 30, 2013 and 2012, 288,420 and 363,794 additional shares of common stock were issuable upon the conversion of outstanding convertible debt agreements. The effect of the shares that would be issued upon conversion of these debt agreements has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Assets Measured on Recurring Basis (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Balance at beginning of period	$716
Conversion of convertible notes	-81
Change in conversion option valuation	-61
Balance at end of period	$574

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Fair Value Assumptions of Assets (Detail)	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Risk-free interest rate	0.30%
Contractual term	'1 year 6 months 15 days
Expected volatility	51.61%

Selected_Consolidated_Financia2

Selected Consolidated Financial Statement Information - Inventories (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$3,146	$2,477
Work in process	739	688
Finished goods	4,381	3,078
Inventories, total	$8,266	$6,243

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Mar. 29, 2010

Sep. 30, 2013

Jun. 29, 2012

Mar. 29, 2010

Mar. 29, 2010

Mar. 29, 2010

Mar. 29, 2010

Sep. 30, 2013

10-May-13

10-May-13

Sep. 30, 2013

Sep. 30, 2013

Nov. 01, 2013

Nov. 01, 2013

Oct. 01, 2013

Nov. 01, 2013

Nov. 01, 2013

Oct. 01, 2013

Silicon Valley Bank

Silicon Valley Bank

Silicon Valley Bank

Silicon Valley Bank

Silicon Valley Bank

Silicon Valley Bank

Silicon Valley Bank

Partners For Growth

Partners For Growth

Partners For Growth

7-Feb-13

19-Feb-13

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Term Loan From Bank

Term Loan From Bank

Term Loan From Bank

Term Loan From Bank

Term Loan From Bank

Line of Credit

Line of Credit

loan

Maximum

7-Feb-13

7-Feb-13

7-Feb-13

19-Feb-13

19-Feb-13

19-Feb-13

Installment

Minimum

Minimum

Maximum

Minimum

Partners For Growth

Partners For Growth

Partners For Growth

Partners For Growth

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings line of credit

'

'

$12,000,000

'

'

'

'

$15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Initial Interest rate

'

'

8.00%

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity time of term loan

'

'

'36 months

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of principal payments

'

'

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal payments

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payment of debt

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Penalty on debt

'

'

'

'

'

1.00%

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding balance including net unamortized premium

'

'

'

5,847,000

'

'

'

'

'

4,719,000

'

'

'

'

'

'

'

'

'

'

Line of credit expiration date

'

'

'

'

'

'

'

30-Jun-14

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit interest rate

'

'

'

'

'

'

'

1.25%

4.50%

'

'

'

'

'

'

'

'

'

'

'

Borrowings line of credit eligible accounts

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

Floating interest rate

'

'

'

'

'

'

'

'

'

'

2.75%

'

'

'

'

'

'

'

'

'

Number of loans

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

Loan and security agreement

'

'

'

'

'

'

'

'

'

4,500,000

'

5,000,000

1,000,000

1,500,000

'

'

'

'

'

'

Reduce in conversion price

'

'

'

'

'

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

Change in fair value of conversion option

61,000

-388,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt conversion, original debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

'

'

$2,000

'

'

Debt conversion, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65,530

'

'

96,586

'

Conversion price

'

'

'

'

'

'

'

'

'

'

'

'

$15.26

$15.53

'

'

$15.26

'

'

$15.53

Debt_Summary_of_Loans_Outstand

Debt - Summary of Loans Outstanding (Detail) (USD $)	Sep. 30, 2013
7-Feb-13	'
Debt [Line Items]	'
Amount of Loan	$1,000,000
Conversion Price	$15.26
19-Feb-13	'
Debt [Line Items]	'
Amount of Loan	1,500,000
Conversion Price	$15.53
27-Feb-13	'
Debt [Line Items]	'
Amount of Loan	1,500,000
Conversion Price	$15.80
6-Mar-13	'
Debt [Line Items]	'
Amount of Loan	$500,000
Conversion Price	$15.94

Debt_Summary_of_Loans_Converte

Debt - Summary of Loans Converted (Detail) (August 14, 2013, USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
14-Aug-13	'
Debt [Line Items]	'
Amount Converted	$500
Shares Issued Upon Conversion	32,679

Debt_Debt_Maturities_Detail

Debt - Debt Maturities (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Nine months ended June 30, 2014	$3,850	'
2015	6,900	'
Total	10,750	'
Less: Current Maturities	-5,074	-5,095
Long-Term Debt (excluding net unamortized premium)	5,676	'
Add: Net Unamortized Premium	66	'
Long-term debt	$5,742	$7,472

Interest_and_Other_Net_Detail

Interest and Other, Net (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Other Income and Expenses [Abstract]	'	'
Interest expense, net of premium amortization	($281)	($370)
Interest income	7	9
Change in fair value of conversion option	-61	388
Net write-offs upon conversion (option and unamortized premium)	-81	0
Other	-29	-31
Total	($445)	($4)

Stock_Options_and_Restricted_S2

Stock Options and Restricted Stock Awards - Additional Information (Detail)	3 Months Ended		0 Months Ended					1 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 04, 2013	Sep. 11, 2013	Jul. 24, 2013	Jun. 30, 1991	Jun. 30, 2003	Feb. 28, 2009	Jun. 30, 2007	Jun. 30, 2013
	Restricted Stock	Restricted Stock	Performance Shares [Member]	Performance Shares [Member]	Performance Shares [Member]	1991 Stock Option Plan	2003 Stock Option Plan	2007 Equity Incentive Plan	2007 Equity Incentive Plan	2007 Equity Incentive Plan
	Minimum	Maximum		Over-attainment Incentives [Member]	Over-attainment Incentives [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Common stock approved	'	'	'	'	'	485,250	2,458,600	2,509,969	'	'
Shares of common stock granted	'	'	'	'	'	'	'	'	1,941,000	'
Expiration period of options or shares	'	'	'	'	'	'	'	'	'10 years	'
Vesting period	'1 year	'3 years	'	'	'	'	'	'	'3 years	'
Increase in number of shares	'	'	'	'	'	'	'	970,500	'	'
Percentage of common shares increased	'	'	'	'	'	'	'	5.00%	'	'
Increase in number of shares available for grant	'	'	'	'	'	'	'	'	'	475,000
Percentage of outstanding shares	'	'	'	'	'	'	'	'	'	1.90%
Share based compensation arrangement by share based payment award equity instruments other than options grants in period on basis of shareholder return (in shares)	'	'	53,566	'	16,964	'	'	'	'	'
Share based compensation arrangement by share based payment award equity instruments other than options grants in period on basis of annual revenue growth (in shares)	'	'	53,566	16,964	'	'	'	'	'	'

Stock_Options_and_Restricted_S3

Stock Options and Restricted Stock Awards - Stock Options Activity (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013
Number of Options	'
Options outstanding, balance at beginning of period (in shares)	1,739,663	[1]
Options exercised (in shares)	-82,889	[1]
Options outstanding, balance at end of period (in shares)	1,656,774	[1]
Weighted Average Exercise Price	'
Options outstanding at beginning of period (in usd per share)	$9.79
Options exercised (in usd per share)	$9.52
Options outstanding at end of period (in usd per share)	$9.81
[1]	Includes the effect of options granted, exercised, forfeited or expired from the 1991 Plan, 2003 Plan, 2007 Plan, and options granted outside the stock option plans described above.

Stock_Options_and_Restricted_S4

Stock Options and Restricted Stock Awards - Restricted Stock Award Activity (Detail) (Restricted Stock, USD $)	3 Months Ended
	Sep. 30, 2013
Restricted Stock	'
Number of Shares	'
Awards outstanding, balance at beginning of period (in shares)	1,430,130
Awards granted (in shares)	437,237
Awards forfeited (in shares)	-37,103
Awards vested (in shares)	-526,729
Awards outstanding, balance at end of period (in shares)	1,303,535
Weighted Average Fair Value	'
Awards outstanding, balance at beginning of period (in usd per share)	$10.78
Awards granted (in usd per share)	$14.40
Awards forfeited (in usd per share)	$10.96
Awards vested (in usd per share)	$9.70
Awards outstanding, balance at end of period (in usd per share)	$12.98

Common_Stock_Warrants_Common_S

Common Stock Warrants - Common Stock Warrant Activity (Detail) (Common Stock Warrants, USD $)	3 Months Ended
	Sep. 30, 2013
Common Stock Warrants	'
Increase (Decrease) in Common Stock Warrants [Roll Forward]	'
Number of Shares, Common stock warrants outstanding, balance at beginning of period	2,091,718
Number of Shares, Common stock warrants exercised	-424,237
Number of Shares, Common stock warrants outstanding, balance at end of period	1,667,481
Weighted Average Exercise Price, Common stock warrants outstanding, balance at beginning of period (in usd per share)	$8.96
Weighted Average Exercise Price, Common stock warrants exercised (in usd per share)	$9.15
Weighted Average Exercise Price, Common stock warrants outstanding, balance at end of period (in usd per share)	$8.91

Common_Stock_Warrants_Narrativ

Common Stock Warrants - Narrative (Details) (Common Stock Warrants, USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
Common Stock Warrants	'
Class of Warrant or Right [Line Items]	'
Common stock warrants exercised (in shares)	424,237
Adjustments to APIC (in shares)	232,651
Adjustments to APIC	$1,137

Texas_Production_Facility_Addi

Texas Production Facility - Additional Information (Detail) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jul. 02, 2012	Jun. 17, 2009	Sep. 30, 2013	Jun. 30, 2013	Sep. 09, 2009
	Job		Employee		sqft
	Employee
Production Facility [Abstract]	'	'	'	'	'
Agreement lease with PEDC, number of square feet	'	'	'	'	46,000
Corporate job creation agreement date	'	17-Jun-09	'	'	'
Net cash incentive funds	$2,975	'	'	'	'
Additional net cash incentive funds	850	'	'	'	'
Cash incentive funds upon hiring of 75th full time employee at facility	425	'	'	'	'
Number of employees to be maintained for grant of first cash incentive fund	75	'	75	'	'
Cash incentive funds upon hiring of 125th full time employee at facility	425	'	'	'	'
Number of employees to be maintained for grant of second cash incentive fund	125	'	'	'	'
Maximum number of jobs maintained to retain cash incentive	25	'	'	'	'
Net award related to job creation agreement	1,020	'	'	'	'
Funded amount grant from state of Texas under Texas enterprise fund program	510	'	'	'	'
Amount received of Texas enterprise fund program	'	'	340	'	'
Remaining amount received of Texas enterprise fund program	'	'	170	'	'
Cumulative expenses	'	'	3,562	'	'
Deferred grant incentive current liability	'	'	151	156	'
Deferred grant incentive long term liabilities	'	'	$51	'	'

Earnings_Per_Share_Reconciliat

Earnings Per Share - Reconciliation of Numerators and Denominators Used in Basic and Diluted Earnings Per Common Share Computations (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
Numerator	'		'
Net loss	($7,292)		($5,210)
Denominator	'		'
Weighted average common shares – basic (in shares)	24,751,368		20,397,004
Effect of dilutive stock options, warrants, convertible debt (in shares)	0	[1],[2],[3]	0	[1],[2],[3]
Weighted average common shares outstanding – diluted (in shares)	24,751,368		20,397,004
Net loss per common share — basic and diluted (in usd per share)	($0.29)		($0.26)
[1]	At September 30, 2013 and 2012, 288,420 and 363,794 additional shares of common stock were issuable upon the conversion of outstanding convertible debt agreements. The effect of the shares that would be issued upon conversion of these debt agreements has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[2]	At September 30, 2013 and 2012, 1,656,774 and 2,371,198 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[3]	At September 30, 2013 and 2012, 1,667,481 and 2,454,579 warrants, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Earnings_Per_Share_Reconciliat1

Earnings Per Share - Reconciliation of Numerators and Denominators Used in Basic and Diluted Earnings Per Common Share Computations (Parenthetical) (Detail)	3 Months Ended
	Sep. 30, 2013		Sep. 30, 2012
Earnings per share	'		'
Number of anti-dilutive stock options, warrants and convertible debt (in shares)	0	[1],[2],[3]	0	[1],[2],[3]
Warrant	'		'
Earnings per share	'		'
Number of anti-dilutive stock options, warrants and convertible debt (in shares)	1,667,481		2,454,579
Stock Options	'		'
Earnings per share	'		'
Number of anti-dilutive stock options, warrants and convertible debt (in shares)	1,656,774		2,371,198
Convertible Debt Securities	'		'
Earnings per share	'		'
Number of anti-dilutive stock options, warrants and convertible debt (in shares)	288,420		363,794
[1]	At September 30, 2013 and 2012, 288,420 and 363,794 additional shares of common stock were issuable upon the conversion of outstanding convertible debt agreements. The effect of the shares that would be issued upon conversion of these debt agreements has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[2]	At September 30, 2013 and 2012, 1,656,774 and 2,371,198 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[3]	At September 30, 2013 and 2012, 1,667,481 and 2,454,579 warrants, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.